– FRANCE, Rouen –  Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces that it has raised €5m to support the rollout of its robotic platform in strategic European target markets. The company also announced the appointment of Lucien Goffart as CEO.

Dr Philippe Bencteux, founder & president of Robocath, said, “I’m delighted to welcome Lucien Goffart to the company at such a key moment for us with the commercial launch of our first robotic platform. His experience in the industry is undeniable. This appointment has been made at a particularly auspicious time, with our only direct competitor, Corindus Vascular Robotics, having been bought out by Siemens for $1.1 billion (€1bn). I would like to thank our longstanding shareholders, who have once again demonstrated their belief in us by raising this new capital. We are also grateful for the support shown by new shareholders.”

The €5 million ($5.5M) capital injection was provided by longstanding shareholders (GO CAPITAL, NCI, Normandie Participations, M Capital and Supernova Invest) and new funds (Caisse d’Epargne Normandie Innovation, Crédit Agricole innove en Normandie and Unexo, a subsidiary of the Crédit Agricole group). The company previously raised €6.4 million ($7M) in 2017. This new injection will allow Robocath to lay the groundwork for rolling out the R-One™ robotic platform in a number of target European countries.

About Lucien Goffart

With twenty years of experience in interventional cardiology, Lucien Goffart has held a number of key positions in leading companies in the sector. He also has a strong track record of supporting international marketing of new products. His résumé notably includes a position as Business unit manager for France at Boston Scientific, a post he occupied for the last four years, and his recent appointment as an executive board member at Electroducer, a French manufacturer of vascular devices.

Lucien Goffart, CEO of Robocath, added, “It’s an honor for me to begin work today as CEO of Robocath. I’m impressed by the progress the company has made since it was founded and I’m excited to be working with such a young and dynamic team. R-One™ is a unique product that offers several advantages to physicians and, by extension, to patients. It has significant potential on the market, and I’m looking forward to starting clinical studies and writing a brand new page in the history of interventional cardiology.”

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.